Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Neoplasms 2012Carcinoma, Non-Small-Cell Lung 1228Breast Neoplasms 1215Leukemia, Myeloid, Acute 967Neoplasm Metastasis 902Melanoma 778Colorectal Neoplasms 752Multiple Myeloma 725Lymphoma 725Ovarian Neoplasms 675Pancreatic Neoplasms 665Lymphoma, Non-Hodgkin 659Prostatic Neoplasms 657Recurrence 637Precursor Cell Lymphoblastic Leukemia-Lymphoma 585Lung Neoplasms 560Leukemia, Lymphocytic, Chronic, B-Cell 555Glioblastoma 527Leukemia 486Lymphoma, Large B-Cell, Diffuse 440Lymphoma, Follicular 419Brain Neoplasms 415Squamous Cell Carcinoma of Head and Neck 389Stomach Neoplasms 387Carcinoma, Renal Cell 385Myelodysplastic Syndromes 382Carcinoma, Hepatocellular 368Advanced Solid Tumors 357Lymphoma, Mantle-Cell 345Glioma 343

Interventions

vadimezan 1tislelizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Advanced or Recurrent Solid Tumors × Clear all
NCT06541639 2025-03-18

EVM16 Injection As a Single and Combination with Tislelizumab in Solid Tumors

Peking University

Phase 1 Recruiting
78 enrolled
Other solid neoplasm

Advanced or Recurrent Solid Tumors

NCT01285453 2020-12-09

Safety and Tolerability of ASA404 Administered in Combination With Docetaxel in Japanese Patients With Solid Tumors

Novartis

Phase 1 Completed
9 enrolled
Other solid neoplasm

Advanced or Recurrent Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡